Ayala Pharmaceuticals Inc Stock News

REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small

Upgrades Morgan Stanley upgraded the previous rating for Pure Storage Inc (NYSE:PSTG) from Equal-Weight to Overweight. In the second quarter, Pure Storage showed an EPS of $0.32, compared to $0.14 fr

Upgrades According to Credit Suisse, the prior rating for Hudson Pacific Properties Inc (NYSE:HPP) was changed from Underperform to Neutral. Hudson Pacific Properties earned $0.51 in the second quarte

Raymond James raised the price target on AutoZone, Inc. (NYSE: AZO) from $2,350 to $2,500. AutoZone shares fell 0.7% to close at $2,289.80 on Wednesday. Roth Capital cut Ayala Pharmaceuticals, Inc

Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of E

Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share. Scopus BioPharma Inc. (NASDAQ:

Merger brings U.S. management and presence, cash to develop compelling late-stage asset

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducte

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Ayala Pharmaceuticals, Inc. (AYLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ayala Pharmaceuticals, Inc. (AYLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. InMed Pharmaceuticals Inc. (NASDAQ: INM)

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. NeuroBo Phar

Gainers Infobird Co., Ltd (NASDAQ: IFBD) rose 70.8% to $3.16 in pre-market trading after 1:5 reverse stock split takes effect. Digital Media Solutions, Inc. (NYSE: DMS) shares rose 62.5% to $2.08 in

Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.